# AIxMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aixmed

- Industry: Healthcare IT
- Headquarters: Santa Clara, US
- Website: www.aixmed.com
- Total disclosed funding: $7.8M
- Latest round: Series A (Aug 31, 2021)
- Investors on record: 2

## About

Established in 2018 by Samuel Chen and TJ Liu, and founded in California, US, AIxMed, Inc. uses an AI-powered (artificial intelligence) computational platform that enables pathologists to scan 3D cytology samples and extract clinical insights in lesser time. In April 2022, AIxMed, Inc raised an amount of USD 0.50 million in Series A funding.

The company employs artificial intelligence and computer vision to provide pathologists with an intuitive and computational user interface platform that allows them to discover deep insights in cytology samples. The company's platform focuses on urine cytology, cervical cytology, and thyroid cytology to deliver clinical insights acquired from full samples in order to provide fast diagnosis, update results on the cloud, and eliminate manual labor.

## Funding rounds

- Series A, Aug 31, 2021, $7.8M — Taiwania Capital, Silicon Valley Venture Capital

## Investors

- Taiwania Capital (https://capitalatlas.ai/funds/taiwania-capital) — Series A
- Silicon Valley Venture Capital — Series A